marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q1
added 05-15-2024
Merrimack Pharmaceuticals Financial Ratios 2011-2024 | MACK
Annual Financial Ratios Merrimack Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-178.6 | -99.9 | -34.1 | -29.7 | -2.4 | -1.4 | 0.2 | -2.0 | -3.7 | -9.3 | -3.3 | -3.8 | - |
P/S |
- | - | - | - | - | - | - | 2.1 | 6.1 | 7.5 | 9.0 | 7.2 | - |
EPS |
-0.1 | -0.1 | -0.2 | -0.2 | -1.3 | -3.0 | 35.7 | -12.1 | -13.3 | -8.0 | -1.3 | -1.3 | -7.7 |
EV (Enterprise Value) |
205 M | 135 M | 70 M | 76.6 M | 27.6 M | 66.9 M | 43.1 M | 613 M | 774 M | 1 B | 600 M | 469 M | 325 M |
EBITDA per Share |
-0.14 | -0.13 | -0.18 | -0.385 | -1.88 | -4.61 | -6.84 | -7.82 | -11.3 | -6.04 | -11.9 | -12.2 | - |
EV/EBITDA |
-27.0 | -17.3 | -1.0 | -0.8 | -0.2 | -5.1 | -4.9 | -13.6 | -4.0 | -4.0 | - | ||
PEG |
4.21 | 1.98 | 0.72 | -0.36 | -0.04 | 0.01 | 0.0 | -0.22 | 0.06 | -0.24 | 1.05 | -0.05 | - |
P/B |
11.3 | 8.0 | 5.9 | 5.6 | 2.4 | 1.0 | 1.2 | -1.2 | -2.9 | -7.6 | -9.9 | -53.9 | - |
P/CF |
-138.6 | -88.5 | -383.8 | -19.4 | -1.3 | -0.9 | -0.8 | -1.7 | -4.6 | -19.0 | -4.1 | -4.2 | - |
ROE % |
-6.30 | -8.02 | -17.30 | -18.92 | -100.12 | -68.87 | 490.25 | 60.43 | 80.44 | 81.55 | 301.22 | 1400.60 | - |
ROA % |
-6.15 | -7.78 | -16.65 | -18.05 | -86.31 | -45.75 | 402.32 | -186.22 | -62.99 | -52.50 | -68.04 | -61.27 | - |
ROCE % |
-10.87 | -8.98 | -17.42 | -31.31 | -157.52 | -88.92 | -98.17 | 1547.48 | -98.81 | -139.45 | -89.50 | -83.96 | - |
Current Ratio |
43.5 | 33.7 | 26.2 | 21.5 | 6.7 | 5.1 | 4.8 | 0.7 | 1.9 | 1.2 | 2.9 | 3.3 | - |
DSO |
- | - | - | - | - | - | - | 44.2 | 26.5 | 11.8 | 44.7 | 69.1 | - |
DIO |
- | - | - | - | - | - | - | 768.5 | 29493.6 | - | - | - | - |
DPO |
- | - | - | - | - | - | - | 178.7 | 40062.7 | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | 812.7 | 29520.1 | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | 634.0 | -10542.6 | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Merrimack Pharmaceuticals
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
13.93 | - | -0.02 | -0.03 | -0.02 | - | -0.03 | -0.04 | -0.01 | - | -0.04 | -0.06 | -0.05 | - | -0.08 | -0.09 | 0.02 | - | -0.05 | -0.71 | -0.78 | -0.67 | 0.3 | -1.33 | -1.33 | -0.97 | 0.24 | 38.62 | -2.27 | -2.5 | -2.33 | -4.02 | -3.31 | -4.16 | -3.79 | -2.07 | -3.24 | -0.09 | -0.27 | -0.17 | -0.27 | -0.33 | -0.39 | -0.31 | -0.29 | -0.26 | -0.25 | -0.22 | -2.14 | -1.76 | -1.81 | -2.76 | -1.35 |
EBITDA per Share |
- | - | - | - | - | - | -0.04 | -0.04 | -0.01 | - | -0.04 | -0.06 | -0.05 | - | -0.08 | -0.09 | 0.02 | - | 0.1 | -0.53 | -0.66 | - | -1.01 | -1.12 | -1.21 | - | -1.07 | -2.45 | -2 | - | -2.42 | -0.27 | -0.29 | - | -0.3 | -0.15 | -0.27 | - | -0.2 | -0.11 | -0.22 | - | -0.34 | -0.29 | -0.28 | - | -0.22 | -0.2 | -1.93 | - | -1.28 | -2.37 | -1.2 |
ROE % |
85.83 | -4.95 | -8.30 | -10.17 | -11.63 | -7.80 | -11.39 | -11.63 | -13.15 | -13.04 | -19.32 | -22.02 | -24.25 | -12.00 | -16.07 | -13.85 | -61.06 | -118.95 | -134.16 | -123.30 | -99.04 | -68.87 | -67.11 | -70.67 | 490.85 | 490.25 | 516.62 | 525.37 | 14.27 | 60.43 | 73.51 | 84.69 | 76.87 | 80.44 | 63.93 | 68.09 | 73.44 | 81.55 | 148.11 | 211.97 | 263.45 | 301.22 | 605.21 | 870.01 | 1108.09 | 1400.60 | 1026.78 | 677.21 | 374.55 | 21.90 | 6.40 | - | 4.63 |
ROA % |
77.52 | -4.84 | -8.08 | -9.87 | -8.76 | -5.04 | -8.48 | -7.76 | -12.55 | -12.45 | -18.45 | -21.01 | -23.16 | -11.44 | -14.96 | -12.47 | -52.49 | -102.54 | -112.65 | -104.63 | -77.74 | -45.75 | -46.68 | -48.55 | 407.54 | 402.32 | 373.54 | 333.99 | -164.31 | -186.22 | -166.76 | -148.00 | -95.41 | -62.99 | -48.75 | -48.20 | -49.92 | -52.50 | -63.57 | -66.58 | -70.80 | -68.04 | -67.49 | -62.46 | -60.27 | -61.27 | -65.88 | -72.11 | -92.73 | -92.88 | -21.80 | -34.06 | -15.78 |
ROCE % |
-8.94 | -8.14 | -11.97 | -12.96 | -13.54 | -8.33 | -11.92 | -11.69 | -13.28 | -13.16 | -19.46 | -22.16 | -24.40 | -12.41 | -17.30 | -15.90 | -61.98 | -116.38 | -144.84 | -168.40 | -144.15 | -87.22 | -104.84 | -94.01 | -100.66 | -81.79 | -67.65 | -35.90 | 14.26 | 42.13 | 62.94 | 69.61 | 65.44 | 47.23 | 70.46 | 72.87 | 76.39 | 59.86 | 142.51 | 201.93 | 255.29 | 212.35 | 578.68 | 862.37 | 1106.97 | 1046.71 | 1053.12 | 693.21 | 386.68 | 16.50 | 6.42 | - | 5.04 |
Current Ratio |
10.8 | 43.5 | 39.1 | 47.3 | 42.4 | 33.7 | 30.4 | - | 26.0 | 26.2 | 22.4 | 20.6 | 24.0 | 21.8 | 21.8 | 21.8 | 21.8 | 7.2 | 7.2 | 7.2 | 7.2 | 3.0 | 3.0 | 3.0 | 3.0 | 5.6 | 5.6 | 5.6 | 5.6 | 0.2 | 0.2 | 0.2 | 0.2 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.8 | 0.8 | 0.8 | 0.8 | 1.0 | 1.0 | 1.0 | 1.0 | 0.8 | 0.8 | 0.8 | 0.8 |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.9 | 0.8 | 0.6 | - | 36.0 | 16.2 | 30.1 | 8.9 | 10.8 | 10.9 | 32.1 | 68.3 | 78.0 | 29.0 | 47.1 | 59.6 | 74.7 | 70.1 | 67.1 | 53.9 | 79.0 | 102.8 | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 403.1 | 1223.8 | 497.3 | 757.2 | 7373.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.0 | 243.2 | 131.2 | 419.7 | 8824.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 403.1 | 1224.7 | 498.0 | 757.8 | 7373.4 | 36.0 | 16.2 | 30.1 | 8.9 | 10.8 | 10.9 | 32.1 | 68.3 | 78.0 | 29.0 | 47.1 | 59.6 | 74.7 | 70.1 | 67.1 | 53.9 | 79.0 | 102.8 | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 329.1 | 981.5 | 366.8 | 338.1 | -1451.1 | 36.0 | 16.2 | 30.1 | 8.9 | 10.8 | 10.9 | 32.1 | 68.3 | 78.0 | 29.0 | 47.1 | 59.6 | 74.7 | 70.1 | 67.1 | 53.9 | 79.0 | 102.8 | - |
All numbers in USD currency